Changping T. Shan

No. 89 Guhuai Road
Jining, 272000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.

Journal: Biomolecules & biomedicine

Published: April 23, 2026

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China.

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: January 19, 2026

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.

Journal: Cancer communications (London, England)

Published: December 09, 2025

Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study.

Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study.

Journal: BMC cancer

Published: September 05, 2025

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Journal: Cancer communications (London, England)

Published: June 07, 2024

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

Journal: Nature communications

Published: December 28, 2023

Disseminated nocardiosis caused by Nocardia otitidiscaviarum in an immunocompetent host: a case report

Disseminated nocardiosis caused by Nocardia otitidiscaviarum in an immunocompetent host: a case report

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: November 01, 2023

Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.

Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.

Journal: Cancer medicine

Published: October 23, 2021

CircRNA Hsa_circ_0001017 Inhibited Gastric Cancer Progression via Acting as a Sponge of miR-197.

CircRNA Hsa_circ_0001017 Inhibited Gastric Cancer Progression via Acting as a Sponge of miR-197.

Journal: Digestive diseases and sciences

Published: February 15, 2020

MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7.

MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7.

Journal: Biochimie

Published: November 28, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026